Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Auque J is active.

Publication


Featured researches published by Auque J.


Radiotherapy and Oncology | 2001

Efficacy of external fractionated radiation therapy in the treatment of meningiomas: a 20-year experience.

Nicolas Pourel; Auque J; Serge Bracard; Sylvette Hoffstetter; Elisabeth Luporsi; Jean-Michek Vignaud; Pierre Bey

BACKGROUND This is a retrospective analysis of a series of meningiomas treated by radiotherapy. MATERIALS AND METHODS From 1978 to 1997, 45 patients with intracranial meningiomas were referred for external fractionated radiotherapy at Centre Alexis Vautrin. All patients were given 50-70Gy to the tumor bed (median: 56Gy), 1.8-2Gy per fraction. RESULTS Evaluation was performed in June 1999 using the Kaplan-Meyer actuarial method with a median follow-up of 30 months (range: 1-166), relapse-free survivals (RFSs) were 75% at 5 years and 67% at 8 years; overall survival (OS) was 74% at 5 and 8 years. For the 26 benign histologically documented lesions, RFSs were 95% at 5 years and 81% at 8 years; OS was 85% at 5 and 8 years. One major radiation-induced complication occurred in this series (decline of cognitive function). According to the indication of radiotherapy, we divided the series into four groups: postoperative irradiation after a first subtotal resection (11 patients), 5-year RFS was 90%; after first recurrence (+/-salvage surgery, 14 patients), 73%; after further recurrence (+/-salvage surgery, 11 patients), 67%; as exclusive treatment (nine patients), 80%. Atypical and malignant lesions (n=7) all relapsed before 24 months of follow-up, all patients but one died before 42 months. Age at the time of irradiation (> or =60 vs. <60 years) and radiotherapy dose (> or =60 vs. <60Gy) did not influence local control or OS. Atypical and malignant lesions (WHO grades II and III) meningiomas had a worse outcome than benign lesions (WHO grade I, P<0.01). CONCLUSIONS These results compare favorably with previously published data. External fractionated radiotherapy is well tolerated and effective. There is still a debate about the place of radiotherapy in the treatment of meningiomas: after subtotal resection, should radiotherapy be given postoperatively or at the time of progression? Should radiotherapy replace surgery when the risk of postoperative sequellae is high? Prospective randomized trials would be required to address these issues.


Neurosurgery | 2008

ANGIOLEIOMYOMA OF THE CAVERNOUS SINUS : CASE REPORT

Sophie Colnat-Coulbois; Emmanuelle Schmitt; Olivier Klein; Nicolas Weinbreck; Auque J; T. Civit

OBJECTIVEAngioleiomyomas are soft tissue tumors with smooth muscle and vascular components. They are extremely rare in intracranial locations and only three cases have been reported in the literature, including one in the cavernous sinus. Furthermore, long-term follow-up after surgery for a tumor at this site has not been described. We report a new case of intracavernous angioleiomyoma with complete surgical removal and no recurrence after 6 years of clinical and radiological follow-up. CLINICAL PRESENTATIONA 50-year-old patient presented with vertical diplopia resulting from left trochlear nerve palsy. Magnetic resonance examination showed a left intracavernous tumor with hypersignal on T2-weighted images, hyposignal on T1-weighted images, and delayed homogeneous enhancement after gadolinium injection. INTERVENTIONSurgical treatment was completed by a left pterional approach. There was a clear plane separating the tumor from the vascular and nervous elements of the cavernous sinus. Complete tumor resection was achieved. Diplopia improved after surgery. Follow-up did not reveal any recurrence. CONCLUSIONAngioleiomyomas are rare benign tumors with an excellent prognosis after total removal that justifies surgical treatment as the first-line treatment.


Neurochirurgie | 2004

Le xanthoastrocytome pléomorphe. À propos de cinq observations

O. Klein; Y. Grignon; Catherine Pinelli; T. Civit; Auque J; J.-C. Marchal

Resume Objectifs de l’etude Les auteurs presentent une serie de 5 xanthoastrocytomes pleomorphes et analysent les aspects diagnostiques, histologiques et therapeutiques de cette tumeur rare qui affecte surtout l’enfant et l’adulte jeune. Methodes Il s’agit d’un travail retrospectif a partir de cinq patients (trois de sexe masculin et deux de sexe feminin), recenses entre 1985 et 1996. Resultats L’epilepsie est le signe clinique le plus souvent retrouve. La tumeur se situe au niveau temporo-parietal dans deux cas, parietal dans un cas, frontal dans un cas et au niveau de l’hypothalamus et du troisieme ventricule dans un dernier cas. A notre connaissance, nous decrivons le premier cas de xanthoastrocytome pleomorphe localise dans la region de l’hypothalamus/troisieme ventricule. Tous les patients ont ete operes : l’exerese a ete totale pour deux patients, subtotale pour deux autres et partielle dans un cas. Quatre patients ont beneficie d’une radiotherapie adjuvante (deux recidives et transformation maligne et deux diagnostics errones) (dose moyenne d’irradiation encephalique : 44,75 Gy). Deux patients ont ete traites par chimiotherapie adjuvante. Un patient a ete perdu de vue. Deux patients ont presente au moins une recidive. Deux patients sont decedes d’une transformation anaplasique de la tumeur. Deux patients sont actuellement en survie sans recidive a 12 et 16 ans du diagnostic avec une excellente qualite de vie (Glasgow Outcome Scale = I). Conclusion La chirurgie represente le traitement de choix de cette tumeur rare. Le pronostic reste tres favorable (en l’absence de transformation anaplasique), mais une surveillance clinique et iconographique sur le long terme reste indispensable.BACKGROUND AND PURPOSE We present a review of five patients who developed pleomorphic xanthoastrocytomas, presenting the clinical features, pathology findings and therapeutic approach of these rare tumours which almost always occur in children and young adults. METHODS This paper is a retrospective study of five patients (three males and two females), treated from 1985 to 1996. RESULTS Seizure was the most frequent symptom. The tumor was located in the temporal or temporo-parietal lobe in two patients, in the parietal lobe in one, the frontal in one and in hypothalamus and third ventricle in the final patient. To our knowledge, no case of pleomorphic xanthoastrocytoma located in the area of hypothalamus/third ventricle has been reported in the literature. All patients underwent surgery which was complete for two patients, subtotal for two others and partial for one. Four were given post-operative cerebral radiation therapy (two recurrences and malignant transformation and two erroneous diagnoses) (mean dose: 44.75 Gy), for two patients surgery was followed by chemotherapy. One patient was lost for follow-up. Two patients presented at least one tumor recurrence. Two died from malignant transformation. Two patients are alive without recurrence at 12 and 16 years from diagnosis with excellent quality-of-life (Glasgow Outcome Scale=I). CONCLUSION Surgery is the gold standard treatment. Prognosis is very good (except for malignant transformation), so that a close long-term clinical and radiological follow-up is mandatory.


Neurochirurgie | 2008

Hémorragies intracrâniennes et anticoagulants oraux : étude des facteurs pronostiques à partir d’une série de 186 cas

Sophie Colnat-Coulbois; F. Cosserat; O. Klein; G. Audibert; J.-M. Virion; P. Tréchot; Catherine Pinelli; T. Civit; Auque J

Resume Introduction Les hemorragies intracrâniennes au cours d’un traitement anticoagulant sont des accidents rares mais associes a une mortalite elevee. L’âge, l’hypertension arterielle, l’intensite de l’anticoagulation favorisent leur survenue. Les facteurs pronostiques sont mal definis pour ce qui concerne les hematomes sous-duraux. Le but de notre travail etait de determiner les facteurs de mauvais pronostic des hemorragies intracrâniennes associees a un traitement par anticoagulants oraux. Methodes Nous avons etudie retrospectivement 186 patients admis dans notre institution entre 2000 et 2006 pour une hemorragie intracrânienne lors d’un traitement par antivitamine K. L’analyse statistique a ete conduite sur l’echantillon global et sur le sous-groupe des hematomes sous duraux. Le critere de jugement principal etait binaire et portait sur l’evolution (guerison ou deces) croise avec differentes variables. Resultats L’âge moyen de la population etait de 70,6 ans. Cent treize patients presentaient un hematome sous dural. Dans la population globale, l’analyse multivariee retrouvait comme facteur individuel de mauvais pronostic l’âge et le coma a l’admission. En revanche, les cephalees etaient un facteur de bon pronostic. Dans le sous-groupe des patients ayant presente un hematome sous dural, les memes facteurs de mauvais pronostic etaient retrouves. Le caractere chronique de l’hematome serait un facteur de bon pronostic comme les cephalees. Conclusion Certains des facteurs pronostiques identifies ont deja ete mis en evidence pour les hemorragies intracrâniennes en dehors d’un traitement anticoagulant. D’autres comme les cephalees n’avaient jamais ete decrits. Notre etude permet de guider la prise en charge therapeutique de ces patients.


Neurochirurgie | 2006

Les astrocytomes pilocytiques du diencéphale de l’enfant: À propos de sept observations

O. Klein; Y. Grignon; T. Civit; Catherine Pinelli; Auque J; J.-C. Marchal

BACKGROUND AND PURPOSE Pilocytic astrocytoma (PA) is a WHO grade I tumor of the central nervous system mostly arising in children and young adults. Management of diencephalic PA is a difficult challenge. Surgical treatment has to cope with both the difficulties of deep location and eloquent area tumors. MATERIALS AND METHODS We retrospectively reviewed seven pediatric cases (female: 4, male: 3) of diencephalic PA. Opto-chiasmatic tumors were excluded from the series. Mean age at diagnosis was 108 months (9 years) (range: 4 month-18 years), median age was 111 months. Median follow-up for the series was 125 months. Tumor locations were as followed: right thalamus: 2, both thalami: 1, hypothalamus: 3, and right basal ganglia: 1. At the onset, the first symptom was mostly raised intracranial pressure. The delay in diagnosis ranged from 48 hours up to 6 years. TREATMENT a shunting procedure was performed in 3 patients, a direct surgical approach in 5 patients (gross total removal: 2; partial removal: 3) and one patient had only a biopsy. Three children were re-operated. Three patients were treated by radiationtherapy (RT) after surgery. Chemotherapy was delivered for 4 children. RESULTS The overall survival rate was 71.4 months (almost 6 years) (range: 3-184 months). Median survival rate was 42 months (3.5 years). Three children died, two by tumor progression and one death related to late side-effects of RT. Four patients have a good quality of life with GOS I (n = 3) or II (n = 1). We observed tumor regression in two patients at 1 and 17 years after the beginning of treatment. Correct diagnosis was only made for two cases at the initial pathological examination. CONCLUSION The course of diencephalic PA is still unpredictable. The tumor can be controlled by a partial surgical removal, and a residual tumor can sometimes decrease in size after surgery. Gross total removal of these tumors, although difficult, may be performed. With cranial navigation systems, the risk is low. Pathological diagnosis is sometimes difficult to assess.


Neurochirurgie | 2005

Statut de méthylation du promoteur du gène Rarb dans les tumeurs cérébrales gliales de bas et de haut grade: Comparaison avec le tissu sain

O. Klein; Y. Grignon; T. Civit; Auque J; J.-C. Marchal

Resume Le recepteur aux acides retinoiques beta (RARs) est un recepteur nucleaire frequemment deregule en pathologie tumorale. Une etude immuno-histochimique a ete conduite pour etudier le niveau d’expression de ce recepteur dans les noyaux des cellules tumorales gliales (gliomes de bas et de haut grade) ainsi qu’une etude du statut de methylation du promoteur du gene codant ce recepteur sur les memes echantillons tumoraux. Une comparaison avec le tissu sain a ete effectuee. Quarante-huit tumeurs ont ete etudiees (15 glioblastomes, 20 oligodendrogliomes de grade III et 13 oligodendrogliomes de grade II). On retrouve une diminution constante de l’expression de RARs par comparaison avec le tissu sain, quel que soit le grade histologique de la tumeur, suggerant une deregulation de l’expression du gene codant RARs. La methylation du promoteur du gene codant RARs est, par contre, un evenement rare (12,5 % des cas), sauf pour les oligodendrogliomes de grade III (20 %), et n’est donc pas un evenement majeur dans l’origine de cette deregulation. D’autres causes de deregulation de RARs devraient etre recherchees comme la perte d’heterozygotie en 3p24, l’etude de l’ARNm et des interactions de RARs avec d’autres recepteurs aux retinoides.Retinoic acid receptor beta (RARbeta) is a nuclear receptor often deregulated in tumors. An immunohistochemical study was conducted to examine the level of expression of this receptor in the nucleus of glial cell tumors (low and high grade glioma) as well as a study of the methylation status of the gene promoter coding this receptor on the same tumor samples. A comparison with normal tissue was done each time. 48 tumors were eligible for the study (15 glioblastomas, 20 grade III oligodendrogliomas and 13 grade II oligodendrogliomas). A constant decrease of RARbeta expression was found by comparison with normal tissue whatever the histological grade of the tumor, suggesting a deregulation of RARbeta gene expression. Methylation of RARbeta promoter gene was a rare event (12.5% of all cases), except for grade III oligodendrogliomas (20%), and is thus not a major event of this gene deregulation. Other reasons of this deregulation of RARbeta should be studied, such as loss of 3p24 heterozygoty, mRNA studies and RARbeta interactions with other retinoid receptors.


Annales Francaises D Anesthesie Et De Reanimation | 1996

Hémorragies sous-arachnoïdiennes par rupture anévrismale. Chirurgie ou embolisation ?☆

J.-C. Marchal; Jp Lescure; Serge Bracard; Auque J; H Hepner; Gerard Audibert; Mireille Hummer; Luc Picard

Traditionally the aneurysms of the circle of Willis have been an indication for neurosurgery. New technologies of endovascular treatment with electrically detachable coils resulted in a different therapeutical concept since four years. A series including 140 patients has been treated in our institution from 1 January 1992 to 31 December 1994, 94 of them presenting with a subarachnoid haemorrhage.Out of these 140 patients, 84 were treated with surgery, 51 with the endovascular technique, five with surgery after incomplete or unsuccessfull endovascular treatment. Surgery was indicated in patients presenting early after bleeding, devoid of vasospasm, with a favourable Hunt and Hess grading and in aneurysms located in the anterior part of the circle of Willis. Endovascular treatment was indicated in patients admitted with delay, with severe vasospasm, a poor Hunt and Hess grading and in all aneurysms of the vertebrobasilar arterial network. Age was of less importance in comparison to the status of the vessels for selection of the method of treatment. Giant aneurysms are difficult to treat as surgery is faced with the size of the aneurysm itself and endovascular technique with the width of the aneurysmal neck.


Laryngoscope | 1992

Endoscopic pituitary tumor surgery.

Roger Jankowski; Auque J; Claude Simon; J.-C. Marchal; Henry Hepner; Michel Wayoff


Neurosurgery | 1996

Aneurysm clipping after endovascular treatment with coils: a report of eight patients.

T. Civit; Auque J; Jean-Claude Marchal; Serge Bracard; Luc Picard; Henri Hepner


Neurochirurgie | 1997

[Waldenström's macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and Neel syndrome. Apropos of a new case].

Civit T; Coulbois S; Baylac F; Taillandier L; Auque J

Collaboration


Dive into the Auque J's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

O. Klein

University of Lorraine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Moret

University of Grenoble

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge